Highlights & Basics
- Erythema infectiosum classically presents in childhood with a "slapped cheek" appearance followed by a reticular, erythematous eruption that is predominantly found on the extremities and may be preceded by mild systemic symptoms. Adults, more than children, may report arthritis and arthralgias.
- Most cases do not require specific treatment beyond symptomatic therapy and reassurance.
- Infection in pregnant women may result in fetal anemia, hydrops fetalis, or intrauterine death.
- Persistent infection, lasting longer than approximately 3 weeks and accompanied by chronic anemia, may occur in people who have immunosuppression (e.g., patients with HIV, people receiving chemotherapy or immunosuppression following transplant, or patients with congenital immunodeficiencies).
- People with a high red blood cell turnover/destruction (e.g., those with hereditary spherocytosis, sickle cell disease, thalassemia, iron deficiency anemia) may develop transient aplastic crisis.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586-597.[Abstract]
UK Health Security Agency. Parvovirus B19: guidance, data and analysis. Aug 2024 [internet publication].[Full Text]
Cherry JD. Parvovirus infections in children and adults. Adv Pediatr. 1999;46:245-69.[Abstract]
Kimberlin DW, Banerjee R, Barnett ED, et al. Red book: 2024-2027 report of the Committee on Infectious Diseases. 33rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2024.
Centers for Disease Control and prevention. Parvovirus B19 and fifth disease. Nov 2019 [internet publication].[Full Text]
1. Hashimoto H, Yuno T. Parvovirus B19-associated purpuric-petechial eruption. J Clin Virol. 2011;52:269-271.[Abstract]
2. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586-597.[Abstract]
3. Shimohata H, Higuchi T, Ogawa Y, et al. Human parvovirus B19-induced acute glomerulonephritis: a case report. Ren Fail. 2013;35:159-162.[Abstract]
4. Huang RJ, Varr BC, Triadafilopoulos G. Acute fulminant hepatic failure associated with parvovirus B19 infection in an immunocompetent adult. Dig Dis Sci. 2012;57:2811-2813.[Abstract]
5. Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. 2009;48:1713-1723.[Abstract][Full Text]
6. Barah F, Whiteside S, Batista S, et al. Neurological aspects of human parvovirus B19 infection: a systematic review. Rev Med Virol. 2014;24:154-168.[Abstract][Full Text]
7. Molina KM, Garcia X, Denfield SW, et al. Parvovirus B19 myocarditis causes significant morbidity and mortality in children. Pediatr Cardiol. 2013;34:390-397.[Abstract]
8. UK Health Security Agency. Parvovirus B19: guidance, data and analysis. Aug 2024 [internet publication].[Full Text]
9. Cherry JD. Parvovirus infections in children and adults. Adv Pediatr. 1999;46:245-69.[Abstract]
10. Lowry SM, Brent LH, Menaldino S, et al. A case of persistent parvovirus B19 infection with bilateral cartilaginous and ligamentous damage to the wrists. Clin Infect Dis. 2005 Aug 15;41(4):e42-4.[Abstract][Full Text]
11. Azzi A, Morfini M, Mannucci PM. The transfusion associated transmission of Parvovirus B19. Transfus Med Rev. 1999;13:194-204.[Abstract]
12. Yu MY, Alter HJ, Virata-Theimer ML, et al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion. 2010;50:1712-1721.[Abstract]
13. Centers for Disease Control and Prevenion. Emergency preparedness and response: increase in human parvovirus B19 activity in the United States. Aug 2024 [internet publication].[Full Text]
14. European Centre for Disease Prevention and Control. Risks posed by reported increased circulation of human parvovirus B19 in the EU/EEA. Jun 2024 [internet publication].[Full Text]
15. American College of Obstetricians and Gynecologists. Increase in human parvovirus B19 activity in the United States. Aug 2024 [internet publication].[Full Text]
16. Cohen B. Parvovirus B19: an expanding spectrum of disease. BMJ. 1995;311:1549-1552.[Abstract][Full Text]
17. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330:1192-1196.[Abstract][Full Text]
18. Anand A, Gray ES, Brown T, et al. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316:183-186.[Abstract]
19. Kimberlin DW, Banerjee R, Barnett ED, et al. Red book: 2024-2027 report of the Committee on Infectious Diseases. 33rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2024.
20. Bernstein DI, Sahly HM, Keitel WA, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011;29:7357-7363.[Abstract]
21. Bansal GP, Hatfield JA, Dunn FE, et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis. 1993;167;1034-1044.[Abstract]
22. Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 2003;187;675-678.[Abstract][Full Text]
23. Chandramouli S, Medina-Selby A, Coit D, et al. Generation of a parvovirus B19 vaccine candidate. Vaccine. 2013;31:3872-3878.[Abstract]
24. Public Health England. Investigation, diagnosis and management of exposure to viral rash illness in pregnancy. Mar 2019 [internet publication].[Full Text]
25. American College of Obstetricians and Gynecologists. Practice bulletin no.151: cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Jun 2015 [internet publication].[Full Text]
26. Koch WC, Harger JH, Barnstein B, et al. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J. 1998;17:489-494.[Abstract]
27. Rosa C. Rubella and rubeola. Semin Perinatol. 1998;22:318-322.[Abstract]
28. Centers of Disease Control and Prevention. Measles (rubeola): specimen collection, storage, and shipment. Jun 2022 [internet publication].[Full Text]
29. Stoeckle MY. The spectrum of human herpesvirus 6 infection: from roseola infantum to adult disease. Annu Rev Med. 2000;51:423-430.[Abstract]
30. Manders S. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol. 1998;39:383-398.[Abstract]
31. Bratton RL, Nesse RE. St Anthony's Fire: diagnosis and management of erysipelas. Am Fam Physician. 1995;51:401-404.[Abstract]
32. Centers for Disease Control and prevention. Parvovirus B19 and fifth disease. Nov 2019 [internet publication].[Full Text]
33. Crabol Y, Terrier B, Rozenberg F, et al; Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968-977.[Abstract]
34. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol. 1998;105:174-178.[Abstract]
35. Gratacos E, Torres PJ, Vidal J, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis. 1995;171:1360-1363.[Abstract]
36. Fairley CK, Smoleniec JS, Caul OE, et al. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19. Lancet. 1995;346:1335-1337.[Abstract]
37. Selbing A, Jesefsson A, Dahlo LO, et al. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet. 1995;345:660-661.[Abstract]
